LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026

Rhea-AI Summary

LeMaitre Vascular (Nasdaq:LMAT) will release fourth-quarter 2025 financial results on February 25, 2026 after the market close. A conference call is scheduled the same day at 5:00 PM EST to review results, business highlights, and company outlook. The live audio webcast and replay will be available at the company investor website, and registrants receive dial-in details and a PIN.

News Market Reaction – LMAT

-0.23%

-0.23% Session close to close

In the Feb 11 session, LMAT declined 0.23%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets expectations for LeMaitre’s Q4 2025 earnings release on Feb 25, 2026 and the ...

Analysis

This announcement sets expectations for LeMaitre’s Q4 2025 earnings release on Feb 25, 2026 and the related conference call. Recent history shows strong Q3 2025 performance with higher sales and margins plus raised guidance, alongside modest price reactions to news. Investors may focus on whether Q4 results sustain growth trends, capital return policies such as dividends and buybacks, and any updates to the company’s outlook and regional growth drivers.

Key Figures

Q3 2025 sales: $61.0mm Q3 2025 GAAP operating income: $20.3mm Q3 2025 diluted EPS: $0.75 +5 more

8 metrics

Q3 2025 sales $61.0mm Reported Nov 6, 2025

Q3 2025 GAAP operating income $20.3mm Up 54% year-over-year

Q3 2025 diluted EPS $0.75 Up 54% year-over-year

Adjusted gross margin 70.8% Q3 2025, up 300 bps

Quarterly dividend $0.20/share Declared for payment Dec 4, 2025

Share repurchase authorization $75.0mm Program through Feb 17, 2026

FY 2025 mid sales guidance $248mm Implied +13% growth

Conestoga ownership 6.73% 1,527,429 shares as of 12/31/2025

Historical Context

4 past events · Latest: Nov 06 (Positive)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 06	Earnings results	Positive	+1.4%	Q3 2025 beat-style metrics with raised full-year 2025 guidance.
Oct 09	Earnings date	Neutral	-1.4%	Announcement of Q3 2025 release timing and conference call details.
Nov 12	Investor conferences	Neutral	-0.4%	Participation in multiple late-2025 investor healthcare conferences.
Aug 28	Investor conferences	Neutral	+0.1%	September 2025 conference schedule with several major brokers.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent earnings and conference announcements have produced modest, mixed single-day moves, suggesting limited but consistent trading reactions to routine corporate updates.

Recent Company History

Over the last six months, LeMaitre reported strong Q3 2025 results, including higher sales, margin expansion, and raised FY 2025 guidance, which coincided with a modest +1.43% move. Earlier, an announcement of the Q3 2025 earnings date on Oct 9, 2025 saw a small decline, while conference-participation press releases in Aug and Nov 2025 generated minimal price impact. Today’s Q4 2025 earnings date notice fits this pattern of routine, low-volatility disclosures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.

Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at www.lemaitre.com/investor.

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.

LeMaitre and the LeMaitre logo are registered trademarks of LeMaitre Vascular, Inc.

Contact:
Gregory Manker
Director, Business Development & Investor Relations
LeMaitre Vascular, Inc.
+ 1-781-362-1260
gmanker@lemaitre.com

FAQ

When will LeMaitre Vascular (LMAT) report fourth-quarter 2025 earnings?

LeMaitre will report fourth-quarter 2025 results on February 25, 2026, after the market close. According to the company, the announcement will be followed by a 5:00 PM EST conference call the same day to discuss results, business highlights, and company outlook.

How can investors access the LeMaitre (LMAT) February 25, 2026 earnings call?

Investors can join the earnings call by registering online to receive dial-in information and a PIN. According to the company, the live audio webcast is available on the company investor website and a replay will be posted for later access.

What topics will LeMaitre (LMAT) cover on the February 25, 2026 conference call?

The call will cover fourth-quarter results, business highlights, and company outlook for the coming periods. According to the company, management will discuss financial results and strategic updates and answer questions from registrants during the 5:00 PM EST call.

Where will LeMaitre (LMAT) post the earnings webcast replay and call materials?

The audio webcast replay and any call materials will be posted on the company's investor website. According to the company, investors can access the live webcast or replay at www.lemaitre.com/investor after the February 25, 2026 announcement.